PLANTATION, Fla., Oct. 11 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to present at the
BIO Emerging Company Investor Forum on Friday, October 15th in San Francisco.
This event is hosted by Lazard and Banc of America Securities and co-hosted by
CIBC World Markets, Pacific Growth Equities and Citigroup.
Viragen's President and CEO, Mr. Charles A. Rice, will provide a strategic
update on the Company, including a discussion of Viragen's product pipeline
with an emphasis on Multiferon(R) and the recently reported 7-year follow-up
to a Phase II/III study for malignant melanoma that resulted in a
statistically significant increase in overall survival.
Event: Viragen Presentation at the BIO Emerging Company Investor Forum
When: Friday, October 15th at 11:30 a.m. (Pacific Time)
Where: The Palace Hotel, San Francisco, California
To Register: Please visit http://www.bio.org
To Schedule an Appointment with Viragen at the Event:
Contact Douglas Calder at 954-233-8746 or at dcalder@viragen.com
In other news, Viragen confirmed that its new manufacturing facility in
Sweden is now ready for Multiferon(R) production as demand dictates.
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and a peptide drug. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's
majority owned subsidiary, Viragen International, Inc., is publicly traded on
the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners and
licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center,
Cancer Research UK, University of Nottingham (U.K.), University of Miami,
America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "will," "should," "could" or similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results to be materially different
from any future results, performance or achievements expressed or implied by
such statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made. Guests scheduled to present at this event are
potentially subject to be replaced, rescheduled or canceled due to unforeseen
conflicts.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
http://www.bio.org
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
